Announcement on Japanese Representation Business Agreement between Richmond Pharmacology and ACRONET Corporation.

Posted:
15
November 2010

We are pleased to announce that ACRONET Corporation (Head office: Bunkyo-ku, Tokyo, President & CEO: Mr Hisashi Uematsu, hereafter referred to as ACRONET) and Richmond Pharmacology Ltd (Head office: St George�s University of London, England, UK, Managing Director: Dr. J�rg T�ubel, hereafter referred to as Richmond) recently executed the Japanese representation agreement. Hereafter ACRONET, as the Japanese representative of Richmond, will start to assist Japanese pharmaceutical companies prior to and during the conduct of their early phase clinical studies by Richmond.

The UK has an established reputation as the preferred country for drug development in the EU. This is because the UK has a stable environment supporting drug discovery through all clinical phases due to the proactive promotion of drug development by the government.Also, due to the established regulatory environment, the UK provides an ideal location for conducting clinical studies and efficient new drug applications.

Consequently, the UK has traditionally produced many excellent companies related to pharmaceutical drug development. Richmond Pharmacology, as an excellent CRO in the UK, has to date supported many pharmaceutical companies, including Japanese Pharmaceutical companies.Because of this situation, ACRONET and Richmond executed the representation agreement to support Japanese pharmaceutical companies for there early phase clinical studies.

Hereafter, as a Japanese representative of Richmond, ACRONET will promote co-marketing activities together with Richmond and act as a contact and a liaison point in Japan to assist Japanese Pharmaceutical companies for their successful Phase I and POC studies, aiming for reducing cost and shortening period for drug development. We will commence sales and marketing promotion for RPL services from September 2009 and hope to achieve annual sales ca JPY 200 million in the total amount of signed contracts.

View Press Release

Latest news

Upcoming Event

ACCP 2020, Translating Clinical Pharmacology Research into Patient-centered Care

21 - 23 September 2020
Dr. Jorg Taubel will be presenting posters that explore the subjects of cardiac health and diabetes.
View event

Richmond Pharmacology is delighted to confirm partnership with Intellia Therapeutics

October 20, 2020
Phase I study of Intellia Therapeutic’s NTLA-2001 for the treatment of hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN)
Read more

Richmond Pharmacology supports ReViral with the development of Sisunatovir

September 9, 2020
ReViral has confirmed the FDA has granted Fast Track designation to Sisunatovir.
Read more

Richmond Pharmacology helps UK patients gain early access to ultra-rare disease drug Lumasiran

August 17, 2020
Richmond Pharmacology early phase drug development update.
Read more